Hepatocellular carcinoma (HCC) is a leading cause of liver-related death worldwide.
Hepatitis C virus (HCV) infection is a major cause of advanced hepatic fibrosis and cirrhosis …

Background & Aims Retrospective studies have found an unexpectedly high incidence of
hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV)-associated …

Hepatitis C virus (HCV) infection and its complications have been the major cause of
cirrhosis and its complications for several decades in the Western world. Until recently …

Background & Aims All oral direct acting antivirals (DAA) have been shown to improve the
liver function of patients with decompensated cirrhosis but it is presently unknown whether …

Background & Aims Direct-acting antivirals (DAAs) have dramatically improved the outcome
of patients with hepatitis C virus (HCV) infection including those with decompensated …

Background & Aims HCV-infected patients with cirrhosis achieve high sustained virological
response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic …

Direct-acting antiviral (DAA) regimens are safe and effective at eradicating hepatitis C virus
(HCV) infection. Unfortunately, DAAs remain expensive, so treatment of all HCV-infected …

Direct‐acting antiviral (DAA) therapy, recently approved for patients with decompensated
cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hepatic …

Background & Aims The effectiveness of direct-acting antivirals (DAAs) against hepatitis C
virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has …

Metabolomics has emerged as an invaluable tool that can be used along with genomics,
transcriptomics and proteomics to understand host–pathogen interactions at small-molecule …